The PREOPANC-1 trial indicated a trend towards longer survival with gemcitabine-combined neoadjuvant radiotherapy compared to upfront surgery; however, this did not reach statistical significance [ 57 ].
1
—
—
The PREOPANC-1 trial indicated a trend towards longer survival with gemcitabine-combined neoadjuvant radiotherapy compared to upfront surgery; however, this did not reach statistical significance [ 57 ].